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Abbreviations:  
AF- Atrial fibrillation 
ARR-Absolute risk reduction 
CKD-Chronic kidney disease 
CMB-Cerebral microbleeds 
CrCL- Creatinine clearance 
CV-Cardiovascular 
ESRD-End stage renal disease 
FFP-Fresh frozen plasma 
GI-Gastrointestinal 
HR-Hazard ratio 
ICH-Intra cranial hemorrhage 
INR-International Normalized Ratio 
MRI-Magnetic resonance imaging 
NOAC-Non-vitamin K antagonist oral anticoagulant 
OAC-Oral anticoagulant 
OR-Odds ratio 
PCC-Prothrombin complex concentrate 
RR-Relative risk 
TTR-Time in therapeutic range 
VKAs-Vitamin K antagonists 
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Abstract 
Atrial fibrillation (AF) is associated with a 5-fold greater risk of ischemic stroke or systemic 
embolism compared with normal sinus rhythm. Cardioembolic AF-related strokes are often more 
severe, fatal or associated with greater permanent disability and higher recurrence rates than 
strokes of other aetiologies. These strokes may be effectively prevented with oral anticoagulant 
(OAC) therapy, using either vitamin K antagonists (VKAs) or non-vitamin K antagonist oral 
OACs (NOACs)  such as the direct thrombin inhibitor dabigatran or direct factor Xa inhibitors 
rivaroxaban, apixaban or edoxaban. Most AF patients have a positive net clinical benefit from 
OAC, excluding those with AF and no conventional stroke risk factors. Balancing the risks of 
stroke and bleeding is necessary for optimal use of OAC in clinical practice, and modifiable 
bleeding risk factors must be addressed. Concerns remain over ‘non-changeable’ bleeding risk 
factors such as older age, significant renal or hepatic impairment, prior stroke(s) or prior 
bleeding event(s) and active malignancies. Such AF patients are often termed ‘special’ AF 
populations, due to their ‘special’ risk profile that includes increased risks of both 
thromboembolic and bleeding events, and due to fear of bleeding complications these AF 
patients are often denied OAC. Evidence shows, however, that the absolute benefits of OAC are 
the greatest in patients at the highest risk, and NOACs may offer even a greater net clinical 
benefit compared to warfarin particularly in these high risk patients.  
In this review article, we summarize available data on stroke prevention in AF patients at 
increased risk of both stroke and bleeding and discuss the use of NOACs for thromboprophylaxis 
in these ‘special’ AF populations.  
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Introduction 
Atrial fibrillation (AF) is associated with a 5-fold greater risk of  thromboembolic events 
compared with normal sinus rhythm (NSR) [1]. Without treatment, approximately one in three 
AF patients would ultimately suffer an ischemic stroke, most often of cardioembolic or far less 
commonly of atherothrombotic origin [2, 3]. Cardiembolic AF-associated events predominantly 
result from dissemination of thrombus formed in the left atrial appendage, and such strokes are 
often more severe, more fatal or associated with greater permanent disability and higher 
recurrence rates than strokes of other aetiologies [3-5]. 
Cardioembolic AF-related strokes may be effectively prevented with oral anticoagulant (OAC) 
therapy, using either vitamin K antagonists (VKAs) or non-vitamin K antagonist OACs 
(NOACs) such as the direct thrombin inhibitor ,dabigatran, or direct factor Xa inhibitors, 
rivaroxaban, apixaban or edoxaban [6-10]. Treatment with VKAs provides a positive net clinical 
benefit in almost all AF patients (excluding those with no conventional stroke risk factors), 
regardless of the bleeding risk level [11, 12]. Compared with VKAs, NOACs may offer even a 
greater net clinical benefit, particularly in AF patients at increased risk of bleeding [13, 14].   
Balancing the stroke and bleeding risks is necessary for optimal use of OAC in clinical practice 
[15-19], and modifiable bleeding risk factors such as poorly controlled hypertension, low quality 
of VKA treatment (as reflected through labile International Normalized Ratios [INR]), co-
medication (e.g., antiplatelet or non-steroidal anti-inflammatory drugs) or alcohol abuse must be 
corrected [20, 21]. Concerns remain over ‘non-changeable’ bleeding risk factors such as older 
age, significant renal or hepatic disease, prior stroke(s) or prior bleeding event(s) and 
malignancy. Such AF patients are often termed ‘special’ AF populations, due to their ‘special’ 
risk profile that includes increased risks of both thromboembolic and bleeding events [17]. In 
these populations the use of OAC might be challenging and more data are needed to better define 
optimal stroke prevention and diminish often unjustified underuse of OAC in the high-risk AF 
patients [22].  
In this review article, we summarize available data on stroke prevention in AF patients at 
increased risk of both stroke and bleeding and discuss the use of NOACs for thromboprophylaxis 
in these ‘special’ AF populations. 
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Elderly patients with AF 
Over a half of AF patients are >75 years old [23]. Advancing age is among the strongest 
independent stroke risk factors, with relative risk (RR) of 1.5 per decade (95% Confidence 
Interval [CI], 1.3-1.7) [24, 25] and stroke rates of up to 36.2% at age of 80-89 years [26]. The 
lifetime AF-related stroke incidence sharply increases during the sixth decade of life, reaching 
the threshold for OAC at 65 years even in the absence of other risk factors [17-19].  
Recently a significant overall decline in the annual stroke rates (from 2.09% to 1.66%, p<0.001) 
in AF patients taking warfarin has been reported, but the risk was still higher in elderly (≥75 
years) compared with younger patients [27]. The rates of warfarin-related major bleeding 
(including intracranial haemorrhage [ICH]) also increased with aging (from 4.7% in those 
younger than 80 years to 13.1% per 100 patient-years in older patients) [28], and each year at 
least 1% of the latter are hospitalized due to gastrointestinal (GI) bleeding [29]. VKAs are often 
underused in older AF patients [30, 31] and, when warfarin is prescribed, those ≥80 years old 
were more likely to discontinue the drug within the first year of treatment (26%) [28].    
A recent report from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) 
Pilot General Registry suggests that antiplatelet therapy (mainly aspirin, alone or in combination 
with OAC) is still frequently prescribed in clinical practice (30.7%), particularly in patients at 
high risk of stroke (as measured by the CHA2DS2-VASc score of ≥2) or bleeding (the use of 
antiplatelet drugs increased from 8.7% in patients with a HAS-BLED=0 to 29.4% in those with a 
HAS-BLED=4) [32]. This persistent misperception of lower bleeding risk with aspirin compared 
to OAC most likely stems from results of the historical randomized trials on warfarin vs. aspirin 
for stroke prevention in AF [6]. A meta-analysis of participants aged ≥75 years showed a 2.2% 
lower risk of ischemic stroke at the cost of a 1.7% greater risk of major bleeding with warfarin, 
but older patients were significantly under-represented in those trials [33].  
In contrast to these historical data, a contemporary, adequately powered, randomized, controlled 
trial on adjusted-dose warfarin (target INR of 2.0-3.0) vs. aspirin 75mg daily for stroke 
prevention in elderly AF patients (all ≥75 years old, mean age 81.5 years) showed no significant 
difference in the rates of haemorrhagic strokes (0.5% vs. 0.4%), other ICH (0.2% vs. 0.1%) or 
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extracranial bleeding (1.4% vs. 1.6%) with warfarin vs. aspirin (all p>0.05) [23]. Overall, there 
was no difference in the annual rates of major bleedings (1.9% vs. 2.0%, RR 0.97; 95%CI, 0.53-
1.75), and the primary endpoint of fatal or disabling stroke, other ICH or arterial embolism was 
significantly reduced by warfarin in comparison to aspirin (RR 0.48; 95%CI, 0.28-0.80, 
p=0.003), with no significant interaction between age and treatment [23]. Aspirin was also 
associated with more adverse events (including bleeding) than warfarin in another trial on 
octogenarians with AF [34].         
In the absence of formal contraindications, warfarin is often denied to older AF patients due to 
concerns such as frailty and the risk of falling, or anticipated non-adherence to therapy 
(secondary to the need for regular INR monitoring or cognitive impairment) [35-37] resulting in 
a poor quality of warfarin therapy as measured by the time in therapeutic range (TTR), thus 
increasing the risk of both thromboembolic and bleeding events [38, 39]. With respect to falling, 
however, it has been estimated that an elderly patient taking warfarin would have to fall 295 
times per year for the risk of warfarin-related bleeding to outweigh the benefit from 
cardioembolic stroke prevention [40]. Indeed, the overall benefit from warfarin was positive in 
elderly AF patients at risk of fall, even in the setting of an increased risk of bleeding [41, 42]. A 
recent ‘real world’ study reported that a small proportion of AF patients actually did have a 
history of prior falls (1.1% of >7000 patients) [43]. A history of falls was associated with 
increased risk of stroke, bleeding and all-cause mortality (all p<0.05), but there was no 
significant association of prior falls and the risk of haemorrhagic stroke under OAC (p=0.16).      
Overall, randomized trials of NOACs vs. warfarin showed that NOACs were non-inferior 
(dabigatran 110mg twice daily, rivaroxaban 20mg once daily, edoxaban both 60mg and 30mg 
once daily) or better than warfarin (dabigatran 150mg twice daily, apixaban 5mg twice daily) for 
the prevention of any stroke or systemic embolism in AF patients [7-10]. Although pertinent 
subanalyses [44-48] uniformly showed higher rates of cardiovascular (CV) events and bleeding 
in patients aged ≥75 years (as compared to those <75 years old) in all treatment arms, there was 
no significant treatment-by-age interaction with respect to the efficacy (i.e., NOACs were as 
effective in elderly AF patients as in the main trials) [44-47, 49, 50].  
Regarding the primary safety outcome of major bleeding, NOACs were as safe as warfarin 
(dabigatran 150mg, rivaroxaban) or safer (dabigatran 110mg, apixaban, edoxaban in both doses) 
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in the main trials, but all NOACs significantly reduced the risk of haemorrhagic stroke or any 
intracranial bleeding compared with warfarin [7-10]. However, there was a significant treatment-
by-age interaction with dabigatran regarding extracranial bleeding. Compared with warfarin, 
dabigatran110mg was associated with a lower risk of major bleeding in patients aged <75 years 
and similar risk in those ≥75 years old, whilst dabigatran 150mg was associated with lower risk 
of major bleeding in patients younger than 75 years and a trend towards greater risk in older 
patients (p=0.07, interaction p<0.001) [44]. A significant interaction has been also reported for 
rivaroxaban, with higher rates of clinically relevant non-major bleeding in the rivaroxaban arm 
compared with warfarin in AF patients aged ≥75 years (15.6% vs. 9.2%), whilst the rates were 
similar in both treatment arms in patients <75 years old (9.2% vs. 9.9%), interaction p=0.01 [48, 
49]. All other effects of rivaroxaban were consistent to the main trial in all age groups. 
There was no significant treatment-by-age interaction either for the efficacy or the safety of 
apixaban [47]. Apixaban effects were consistent across all subgroups of patients aged ≥75 years 
(e.g., different levels of chronic kidney disease, warfarin-naive patients, etc.), with significant 
interaction only between treatment and individual TTR (the reduction in major bleeding with 
apixaban vs. warfarin was greater in elderly patients with low vs. high predicted TTR, interaction 
p=0.029). Importantly, there was no significant interaction of treatment and apixaban dose (790 
patients aged ≥75 years received a reduced dose of 2.5mg twice daily) [47].  
In the AVERROES trial comparing apixaban with aspirin for stroke prevention in AF patients 
unsuitable for warfarin, apixaban significantly reduced the risk of stroke or systemic embolism 
(Hazard Ratio [HR] 0.45; 95%CI, 0.32-0.62, p<0.001), with no difference in the risk of major 
bleeding (HR 1.13; 95%CI, 0.74-1.75, p=0.57) or ICH (HR 0.85; 95%CI, 0.38-1.90, p=0.69) 
between the treatment arms, and the effects of apixaban were consistent in all age groups [51].   
The ENGAGE-AF trial compared edoxaban 60mg once daily (high-dose) and 30mg once daily 
(low-dose) vs. dose-adjusted warfarin for stroke prevention in non-valvular AF; however, in both 
treatment arms edoxaban dose was halved for patients with any of the following conditions: body 
weight <60kg, creatinine clearance <50ml/min or verapamil or quinidine use (25.4% of patients 
received the reduced dose at randomization in both edoxaban treatment arms) [10]. There was no 
significant interaction between age and treatment effects of edoxaban.  
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A pooled meta-analysis of the trials comparing NOACs vs. warfarin for thromboprophylaxis in 
patients with non-valvular AF showed no significant interaction of the NOACs effects with age 
[52]. Hence, age itself should not preclude the use of OAC in AF patients. Due to a greater risk 
of stroke in elderly AF patients, any OAC should be preferred over aspirin or no therapy, and 
NOACs may offer a greater net clinical benefit than VKAs in this patient population, due to 
significantly lower risk of haemorrhagic stroke or any other ICH with NOACs compared to 
warfarin. Individual patient and drug characteristics should influence the choice of particular 
NOAC for a given patient.     
 
Patients with chronic kidney disease  
Nearly a third of patients with chronic kidney disease (CKD) have AF [53], and up to 50% of AF 
patients may have some degree of renal dysfunction [54]. The incidence and prevalence of AF 
increase with increasing severity of renal dysfunction [55, 56] and incident AF further increases 
the risk of end-stage renal disease (ESRD), with HR of 1.67 (95%CI, 1.46-1.91) [57].  
Patients with CKD or AF carry a larger burden of associated CV diseases compared to 
individuals with normal heart rhythm and normal renal function [53, 58]. In addition, patients 
with both AF and CKD have higher mortality than those with AF or CKD only [59]. Both AF 
and CKD are associated with increased annual risk of ischemic stroke (5% and 4%, respectively) 
[1, 60], and stroke risk increases with the severity of CKD (Table 1) [60]. Whilst the occurrence 
of AF in non-end-stage CKD patients clearly adds to the risk of stroke [59, 61], data on the 
association of incident AF with an additional increase in the (already high) risk of stroke in 
patients with ESRD requiring dialysis are inconsistent [57, 59, 61-65]. Although AF patients 
with stage III/IV CKD (Table 1) have sufficiently high absolute stroke risk to warrant oral 
anticoagulation, such therapy may be challenging for a number of considerations including the 
greater risk of bleeding compared to patients with normal renal function [53, 59, 66]. Indeed, in a 
large outpatient cohort, stage IV CKD has been identified as a multivariable predictor of major 
haemorrhage during warfarin therapy [67].    
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Mild to moderate CKD (Stages II-III) in AF patients.   
In a subgroup analysis of a randomized trial adjusted-dose warfarin significantly reduced the 
relative risk of stroke by 76% (95%CI, 42-90) compared with aspirin plus low doses warfarin in 
AF patients with stage III CKD [68]. However, in a large observational trial, the use of warfarin 
in AF patients with non-ESRD was associated with stroke reduction at the cost of increased 
bleeding risk (HR 1.36; 95%CI, 1.17-1.59, p<0.001), particularly in patients aged ≥65 years (HR 
1.61; 95%CI, 1.35-1.95) [59]. Of note, aspirin was also associated with increased bleeding risk 
but, in contrast to warfarin, there was no benefit with aspirin for reducing thromboembolism in 
the trial cohort. 
Subgroup analyses of the NOACs trials uniformly reported greater thromboembolic and bleeding 
rates in AF patients with mild to moderate CKD compared to those with normal renal function in 
all treatment arms [69-72], and the risk of major bleeding increased with decreasing creatinine 
clearance (CrCl) [45, 46]. NOACs are eliminated via the kidneys to a variable extent, with a 
proportional prolongation of their half-lives relative to the degree of renal dysfunction [7-10]. 
Dabigatran has the greatest extent of renal elimination (80% of the dose) [73]. Patients with 
severe CKD (CrCl of <25-30mL/min) were excluded from the NOACs trials [7-10, 51].  There 
was also a drug dose adjustment in patients with moderate CKD in ROCKET-AF and ENGAGE-
AF, as well as in the ARISTOTLE, and AVERROES and ENGAGE-AF trials, where the 
apixaban dose was halved to 2.5mg twice daily if increased serum creatinine of ≥133μmol/l was 
combined with age ≥80 years and/or body weight ≤60kg)  [8-10, 51].   No dose adjustment on 
basis of renal function was performed in RELY, although CrCl <30mL/min was an exclusion 
criteria. 
With respect to the primary efficacy endpoint of any stroke or systemic embolism, there was no 
statistically significant interaction between treatment and renal (dys)function (NOACs were as 
effective in patients with mild to moderate CKD as in the main trials) [69-72]. Regarding the 
primary safety endpoint, there was a significant interaction between the effect of apixaban and 
renal dysfunction in the way that apixaban was even safer in patients with mild, and particularly 
with moderate CKD (the major bleeding rates in this subgroup were halved with apixaban 
compared to warfarin) [71]. There were no significant safety interactions relative to renal 
function with other NOACs [69, 70, 72], including edoxaban (as per the primary publication of 
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the trial results) [10]. Importantly, rivaroxaban and apixaban dose reduction in AF patients with 
moderate CKD did not affect their efficacy and safety in these patients [70-72].   
Overall, in a pooled individual patient data meta-analysis, NOACs as a whole were better than 
warfarin in the reduction of any stroke or systemic embolism in patients with moderate CKD 
(RR 0.79; 95%CI, 0.65-0.96), with similar major bleeding risk in both treatment groups (RR 
0.74; 95%CI, 0.52-1.05), and there was no significant treatment interaction with renal function 
(interaction p 0.12 and 0.57, respectively) [52]. Regarding the comparison of apixaban with 
aspirin, apixaban was as effective and safe in patients with moderate CKD as in all other AF 
patients unsuitable for aspirin in the AVERROES trial [72]. All NOACs consistently reduced the 
risk of ICH compared with either warfarin or aspirin, irrespective of the renal function [69-72]. 
Given these advantages of NOACs, these drugs should clearly be preferred over warfarin (or 
aspirin) for stroke prevention in patients with AF and mild-to-moderate renal dysfunction.     
Advanced CKD in AF patients.  
Whilst being excluded from the RE-LY, ROCKET-AF and ENGAGE-AF trials, small numbers 
of patients with stage IV CKD (CrCl of 25-29 mL/min) participated in the ARISTOTLE and 
AVERROES trials (n=270 and n=70, respectively), but no results from these subsets have been 
published [9, 72]. Rivaroxaban 15mg once daily has been approved for AF patients with stage IV 
CKD in the United States of America and Europe, whilst dabigatran 75mg twice daily has been 
approved in this setting only in the United States. Among the NOACs, only apixaban has been 
recently approved for the use in ESRD patients on haemodialysis (the recommended dose of 5mg 
twice daily should be halved in patients with body weight of ≤60kg and or age ≥80 years).   
Data from randomized trials are also lacking for the use of VKAs in AF patients with stage IV-V 
CKD [74], and observational data on the effects of VKAs in such patients are conflicting. 
Retrospective analyses of 3 large databases of ESRD patients on dialysis failed to show a benefit 
of warfarin in those with AF [62, 75, 76], whilst warfarin (but not aspirin) treatment was 
associated with a significant reduction of stroke or systemic embolism (HR 0.44, 95%CI, 0.26-
0.74, p=0.002) in AF patients requiring renal-replacement therapy in a retrospective large cohort 
study [59]. However, the risk of bleeding among such patients was significantly increased. 
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Overall, the net clinical effect of warfarin therapy in this patient population requires careful 
individual patient assessment [17-19, 77-79]. Importantly, AF patients with ESRD and prior 
stroke are at such high risk of recurrent stroke that the use of well managed warfarin with careful 
INR monitoring seems justified, but patient values and preferences should also be taken into 
account [80, 81]. There is an urgent need for randomized clinical trials of optimal stroke 
prevention in AF patients with ESRD [82].   
 
Patients with prior ischemic stroke  
Previous ischemic stroke (or TIA) is the single most powerful independent risk factor for 
recurrent stroke in patients with non-valvular AF, conferring a 2.5-fold greater risk of new brain 
ischemic event compared to patients without history of stroke [24, 25]. Recurrent strokes are 
often more disabling (or fatal) and costly compared with index stroke [83]. Importantly, prior 
stroke/TIA is also an independent risk factor for bleeding complications of OAC [84].  
Aspirin is not effective in long-term secondary prevention of ischemic stroke in patients with AF 
(HR 0.83; 95%CI, 0.65-1.05) [85]. Combined aspirin and clopidogrel are generally more 
effective than aspirin alone (RR 0.72; 95%CI, 0.62-0.83), but with more major bleeding (RR 
1.57; 95%CI, 1.29-1.92) as shown in AF patients unsuitable for VKAs (however, only 13% of 
patients in that trial had a history of stroke or TIA) [86].  
Two randomized trials investigated the efficacy and safety of warfarin vs. control (aspirin [85] or 
indobufen [87]) in patients with a previous stroke or TIA, and the results were consistent with 
those in the primary prevention of AF-related stroke [6, 83]. There was an impressive reduction 
of recurrent stroke with warfarin (OR 0.49; 95%CI, 0.33-0.72) at the cost of increased risk of 
major extracranial bleeding (OR 5.2; 95%CI, 2.1-12.8), as compared to antiplatelet therapy [83, 
85]. Aspirin plus clopidogrel was also less effective than warfarin (RR 2.13; 95%CI, 1.23-3.69) 
[88]. Overall, the absolute benefits of warfarin therapy in the older trials were the greatest in 
patients at the highest risk of stroke [6, 11].  
Approximately 20% of AF patients included in the recent NOACs clinical trials had a history of 
prior stroke or TIA [52]. The rates of both thromboembolic and bleeding events were higher in 
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this subgroup compared with patients without previous stroke/TIA but the relative efficacy and 
safety of NOACs compared to warfarin (or aspirin) were consistent in patients with and without 
previous stroke/TIA [89-92]. Importantly, all four NOACs were far safer than warfarin in this 
high-risk AF patient population, in terms of the impressive reduction in the risk of cerebral 
haemorrhage and other ICH events [10, 89-91].  
In contrast to individual NOACs trials, which were not sufficiently powered to reliably detect the 
presence (and significance) of differences in NOACs effects compared with warfarin in various 
AF patient subgroups, a meta-analysis of 14,527 AF patients with previous stroke/TIA from the 
RE-LY, ROCKET-AF and ARISTOTLE trials revealed a significant reduction of any stroke or 
systemic embolism with NOACs relative to warfarin (OR 0.85; 95%CI, 0.74-0.99), with absolute 
risk reduction (ARR) of 0.7% and number needed to treat (NNT) of 134 (over 1.8-2.0 years) 
[93]. NOACs were also associated with a significant reduction in major bleeding events (OR 
0.86; 95%CI, 0.75-0.99), with ARR of 0.8% and NNT of 125, and the effect was mostly driven 
by the significant reduction of the haemorrhagic stroke rates (OR 0.44; 95%CI, 0.32-0.62), with 
ARR of 0.7% and NNT of 139 [93]. 
Compared to warfarin, the absolute benefits of NOACs are greater in the secondary stroke 
prevention, due to the higher baseline risk of both thromboembolic and bleeding events in this 
subgroup [93, 94]. Accordingly, even patients with AF and prior stroke/TIA who are unsuitable 
or unwilling to take VKAs should be offered a NOAC instead of aspirin, since in the 
AVERROES trial, for example, apixaban was superior to aspirin, with comparable bleeding risk 
and better tolerability [51, 92]. 
When to start a NOAC after recent brain ischemia?  
The risk of a recurrent stroke within the first two weeks after the index ischemic event averages 
5%-10% [95, 96]. However, within the first 48 hours of acute cardioembolic stroke there was no 
mortality or disability benefit of anticoagulant therapy compared with aspirin (OR 1.14; 95%CI, 
0.95-1.38) or placebo (OR 0.90; 95%CI, 0.62-1.22) [97]. Overall, there was a trend towards 
recurrent stroke reduction (OR 0.68; 95%CI, 0.44-1.06, p=0.09, NNT 53), at the cost of 
significantly increased risk of symptomatic ICH (OR 2.89; 95%CI, 1.19-7.01, p=0.02, NNT 55) 
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and no mortality benefit with anticoagulants versus control (OR 1.01; 95%CI, 0.82-1.24, p=0.9) 
[97]. 
Recent stroke was among the exclusion criteria in all trials of NOACs for stroke prevention in 
AF, with the cut-off set at 30 days (ENGAGE-AF), 14 days (RE-LY and ROCKET-AF) or 7 
days (ARISTOTLE) prior to randomization [7-10]. Of note, a small number of AF patients 
(n=21) were randomized to apixaban 8-14 days after an acute stroke in the ARISTOTLE trial 
and there were no secondary bleeding events in this subgroup. However, the time from 
randomization to treatment is unknown, and most probably those were patients with minor 
strokes [94, 98]. A recent small study of 41 AF patients in whom a NOAC (dabigatran, n=37 or 
rivaroxaban, n=4) was started 1-6 days (median 2 days) post acute ischemic stroke reported no 
recurrent thromboembolic events or bleeding complications during a 3-month follow-up, thus 
suggesting that early NOAC initiation after an ischemic stroke in AF patients might be safe [99].  
Until more data are available, decision about the timing of NOACs initiation in AF patients post 
acute ischemic stroke should include assessment of the index stroke severity (and resulting risk 
of haemorrhagic transformation) and the risk of recurrent thromboembolic event [100]. Whilst a 
NOAC should be initiated immediately after a TIA, the use of NOACs most likely should be 
postponed for 3-5, 7-14 and ≥14 days post mild-to-moderate, moderate-to-severe and severe 
large strokes, respectively [100, 101]. Antiplatelet drugs should be discontinued at the time of 
NOACs initiation unless there is a strong indication other than secondary stroke prevention for 
their continuous use.              
 
Patients with prior intracranial bleeding 
The term ICH encompasses several subtypes of bleeding within the skull – intracerebral 
bleeding (a haemorrhage directly into the brain parenchyma; when causing focal neurological 
symptoms and signs, such bleeding is termed hemorrhagic stroke), subdural haematoma and 
subarachnoid haemorrhage. Intracerebral bleeding accounts for 10%-20% of all strokes and 
generally has worse prognosis than cerebral ischemia [102]. ICH is the most feared and 
devastating complication of OAC, occurring in 0.2%-1% of patients taking OAC [7-10, 27, 50, 
51, 103, 104] and resulting with fatal outcome in ≥40% of cases, whilst at least half of the 
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survivors permanently remain severely disabled [105]. Anticoagulation-associated ICH generally 
has worse prognosis than a spontaneous ICH [106, 107].  
The annual rates of ICH in AF patients taking VKAs ranged from 0.33% to 0.85% in recent 
randomized trials comparing warfarin to other antithrombotic drugs [7-10, 27, 51], with a pooled 
rate of 0.61% (95%CI, 0.48-0.73) per year [27]. Observational studies mostly report higher 
annual rates of anticoagulation-associated ICH, reaching up to 2.5% per year in the inception 
cohorts and elderly AF patients [11, 28, 108-111]. Patients with intracerebral haemorrhage 
during warfarin therapy often present with larger haematoma and have worse functional 
outcomes than patients with normal coagulation status [112, 113]. At presentation, most patients 
with anticoagulation-associated intracerebral bleeding have a therapeutic INR (2.0-3.0) [106, 
107, 114], although supratherapeutic INRs have been also associated with increased 30-day 
mortality [107, 115]. The prevalence of warfarin-associated intracerebral bleeding is still 
increasing, most likely due to increasing use of OAC [116]. Whilst the overall mortality from 
intracerebral bleeding has declined, warfarin-associated intracerebral bleeding mortality is 
unchanged [116]. For example, in an AF cohort, of 72 patients with warfarin-associated 
intracerebral haemorrhage 76% had died or were severely disabled at hospital discharge, whilst 
the mortality from warfarin-associated major extracranial bleeding was only 3% [105]. 
Compared with warfarin, NOACs impressively reduced the risk of ICH in AF patients (Table 2), 
with pooled RR of 0.48 (95%CI, 0.39-0.59) [52], and the effect was consistent across all patient 
subgroups in all NOACs trials [7-10, 51]. A more detailed analysis of the RE-LY and ROCKET-
AF trials with respect to ICH [50, 117] showed that NOAC-related ICHs mostly were 
spontaneous intracerebral bleedings with higher mortality than those of traumatic origin. In the 
RE-LY trial, 108 of 154 ICHs (70%) were spontaneous and associated with higher mortality 
(42%) than traumatic ICHs (24%) [117]. Intracerebral bleeds accounted for 46% of all ICHs 
(n=71), most often were spontaneous (89%) and associated with higher mortality (52%) than 
traumatic intracerebral bleeds (25%), which were infrequent (n=8) and mostly occurred after a 
major head trauma. In the ROCKET-AF trial, 127 of 172 ICHs (73.8%) were intracerebral 
bleedings, of which only 9 (7%) were caused by trauma. ICH-associated 30- and 90-day 
mortality was 43% and 51%, respectively [50]. Whilst the case fatality of ICH was lower with 
both doses of dabigatran, and similar with rivaroxaban compared to warfarin, there were no 
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significant differences in the ICH-associated mortality among the treatment groups (i.e., warfarin 
and both doses of dabigatran or rivaroxaban) [50, 117].  
Clinical trials provided strong evidence of much lower incidence of ICH with NOACs relative to 
warfarin, whilst ICH-associated mortality rates were similar with dabigatran, rivaroxaban and 
warfarin. A recent analysis of a health insurance database also confirmed similar in-hospital 
mortality from anticoagulant-associated ICH in patients taking warfarin or dabigatran [118]. 
Nonetheless, specific clinical data on the effects of NOACs on the intracerebral bleeding 
volume, haematoma expansion and functional outcome are lacking [119]. Both experimental and 
clinical evidence suggest that patients with warfarin-associated ICH have a larger haematoma 
size at presentation, with fluid blood inside the haematoma, a smaller early perihaematomal 
oedema and a higher rate of delayed haematoma expansion resulting in a worse clinical outcome 
compared to ICH patients with normal coagulation status [105, 106, 119-123]. Experimental 
randomized studies consistently showed less detrimental effects of therapeutic levels of 
dabigatran and rivaroxaban on haematoma expansion and functional outcome compared to 
warfarin [124-126]. However, most experiments are run on healthy anticoagulated animals with 
artificially induced ICH and experimental data should be translated with caution into clinical 
setting, wherein ICH commonly occur in elderly AF patients with some comorbidities.   
Evidence suggests a frequent occurrence of cerebral microbleeds (CMB) in AF patients taking 
warfarin and positive correlation between higher CHA2DS2-VASc scores and increasing rates of 
CMBs [127]. CMBs have been shown to be an independent risk factor for anticoagulation-
associated symptomatic ICH [128-130]. CMBs identified by brain magnetic resonance imaging 
(MRI) provide direct evidence of blood leakage from pathologically fragile small vessels, and 
their distribution likely reflects the nature of underlying small vessel disease – strictly lobar 
CMBs localized cortically-to-subcortically are characteristic of cerebral amyloid angiopathy, 
whilst deep CMBs rather reflect hypertensive arteriopathy [111]. Although the former seems to 
be a stronger risk factor for recurrent symptomatic ICH, there are no clear criteria for reliable 
recognition of patients at higher risk of anticoagulation-associated ICH based on MRI [131]. 
Whilst clinical evidence suggest that the occurrence of CMBs in patients taking OAC increases 
the risk of anticoagulation-associated ICH [128-130], experimental data failed to confirm their 
expansion into large parenchymal haematoma under warfarin treatment [119], and there was no 
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increase in the CMBs volume after standard doses of dabigatran and rivaroxaban [124, 126]. 
Importantly, CMBs have been associated with increased risk not only of recurrent ICH, but of 
ischemic stroke as well [132].   
Available experimental and clinical data provided some insight into the differences in 
pathophysiology of ICH occurring during dabigatran or rivaroxaban anticoagulation compared to 
warfarin. In vitro studies showed that deficiencies of the coagulation factors II (thrombin), VII 
and X result in delayed clot formation, with slow propagation and reduced clot strength, thus 
facilitating prolonged bleeding, whilst only a partial restoration of thrombin enabled almost 
normal clot formation [133]. VKAs extensively alter coagulation by affecting factors II, VII, IX 
and X, thus compromising the formation of the complex of tissue factor (factor III) and activated 
factor VII (VIIa), which is the primary cellular driver of coagulation that provides physiological 
haemostatic protection from various injuries. In contrast, dabigatran and rivaroxaban reversibly 
interfere only with one coagulation factor (i.e., factor IIa and Xa, respectively), not affecting the 
formation of tissue factor-VIIa complexes. In addition, dabigatran binds only to the active site of 
the thrombin molecule, leaving the two exosites available for interaction with other components 
of the haemostatic system, and neither dabigatran nor rivaroxaban substantially penetrates the 
blood-brain barrier [125, 126, 134-136]. In brief, it seems that selective inhibition of a single 
coagulation factor allows for feedback mechanisms within the coagulation cascade to maintain 
the necessary haemostasis, thus preventing excessive intracerebral haematoma growth [137]. 
Given that anticoagulation-associated ICH is characterized by prolonged bleeding with delayed 
formation of a fragile clot, and the size of haematoma is a major prognostic determinant of ICH, 
a key therapeutic aim in ongoing ICH is to prevent continued haematoma growth [131]. A rapid 
reversal of anticoagulation to prevent extensive haematoma enlargement is strongly 
recommended [138], although no evidence from randomized clinical trials is available to support 
the expert opinion [119, 131]. Treatment options include vitamin K (reconstitutes the hepatic 
synthesis of the vitamin K-dependent coagulation factors, but anticoagulation reversal occurs 
only after hours to days), fresh frozen plasma (FFP; mostly not available immediately because it 
is stored in blood banks, requires blood compatibility testing, the infusion takes several hours 
and there is some volume overload, which may be challenging in patients with heart failure, for 
example), prothrombin complex concentrates (PCCs; reverse anticoagulation by replacement of 
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coagulation factors, are readily available, the infusion takes minutes, provide faster reversal of 
anticoagulation, with lower red cell transfusion requirement and have fewer adverse effects than 
FFP [139]) and recombinant factor VIIa, which is thought to provide a localized enhancement of 
thrombin generation with a more stable clot formation at the site of injury [140].  
Observational studies suggest that PCCs correct increased INR more rapidly than does FFP, and 
recombinant factor VIIa corrects INR more reliably than do PCCs [141-143]. Reduction of INR 
has been associated with reduced haematoma size, and randomized experimental studies suggest 
that rapid anticoagulation reversal could prevent extensive haematoma enlargement and improve 
functional outcome of anticoagulation-associated intracerebral bleeding [144-146]. The reversal 
of warfarin effect may be easily monitored at bedside, using the point-of-care-devices for INR 
measurement. In patients taking NOACs, however, administration of haemostatic agents has 
variable effects on the coagulation tests, and the extent of laboratory tests reversal is not a 
reliable indicator of sufficient haemostasis to halt anticoagulant-associated bleeding [119, 147]. 
Experimental studies and randomized studies in healthy individuals suggest that both FFP and 
PCC reduce the size of intracerebral haematoma during dabigatran and rivaroxaban 
anticoagulation, whilst recombinant factor VII reduced haematoma size during rivaroxaban 
anticoagulation, but was ineffective in dabigatran-treated animals [148-150]. 
Resumption of OAC after ICH.  
Most AF patients have sufficient thromboembolic risk to warrant long-term OAC, which would 
result in positive net clinical benefit at any bleeding risk level [11, 13]. However, patients with 
anticoagulation-associated acute intracerebral bleeding have a transient short-term risk of 
haematoma expansion and persistent long-term risk of ICH recurrence, both of which are highly 
fatal events [131]. Immediate withdrawal of OAC at the onset of an ICH is mandatory, but it 
leaves the patient at increased risk of ischemic stroke and other thrombotic events (e.g., 
pulmonary embolism, deep vein thrombosis, etc.).  
Unfortunately, there is only limited evidence of whether and when it is safe to restart OAC after 
an intracerebral bleeding. Data from observational case series and stroke registries uniformly 
report high mortality rates in patients with anticoagulation-associated ICH, regardless of whether 
or not warfarin therapy was restarted (in the Canadian Stroke Registry, for example, overall 30-
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day and 1-year mortality was 47% and 57%, respectively) [151]. Not surprisingly, mortality from 
subdural haematoma was lower than mortality from intracerebral bleeding (32% and 52%, 
respectively) [152]. Warfarin therapy has been restarted in about a third of ICH survivors, and 
the rates of recurrent ICH were either similar or higher in patients with OAC compared to those 
without OAC in the two registries (15% each and 14% vs. 8%, respectively), whilst 
thromboembolic event rates were variable (0.8% vs. 0.5% in the Canadian Registry, and 2% vs. 
18% in another registry) [151, 152]. Differences in the thromboembolic event rates most likely 
could be attributed to different patient risk profiles in the registries (e.g., different proportion of 
patients with mechanical valves, AF, etc.).  
In the absence of sufficient quality data and explicit formal recommendations to inform clinical 
decision about resumption of OAC in AF patients who survived an anticoagulation-associated 
ICH, careful patient selection is critical. Although the thromboembolic risk can be lowered by 
resumption of OAC, net clinical benefit may be substantially offset by an increased risk of 
recurrent ICH, which strongly depends on the underlying pre-existent cerebrovascular disease 
and is much higher in patients with lobar intracerebral bleeding than in those who suffered a 
deep cerebral haemorrhage [119]. It has been suggested that the risk of recurrent ICH and 
mortality is sufficiently high to preclude OAC resumption in patients who survived a lobar ICH, 
whilst AF patients post deep cerebral haemorrhage may be considered for OAC in the presence 
of a very high risk of ischemic stroke (e.g., with a CHA2DS2-VASc score of ≥5, although this 
approach has not been formally tested) [153, 154]. Until more data are available, the presence of 
CMBs on MRI should not be used as an absolute exclusion criterion for OAC resumption post 
ICH. The optimal timing of OAC re-initiation post ICH is poorly defined, and available evidence 
suggest that the descending risk of recurrent bleeding crosses the imaginary line of 
thromboembolic risk somewhere at 10 weeks post index anticoagulation-associated ICH (a time 
point when the risks become balanced) [152, 154].  
Once the decision to restart OAC has been made, NOACs should be considered rather than 
warfarin due to their favourable safety profile with respect to ICH. Strict blood pressure control 
is important, and regular clinical follow-up is strongly advised, with renal function assessment 
(with NOACs therapy) and strict INR control (with warfarin). In AF patients with highly 
unfavourable risk/benefit ratio antiplatelet drugs should not be considered as an alternative to 
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OAC, due to their marginal efficacy [6] and no true safety benefit [51, 88], whilst the left atrial 
appendage occlusion could be a viable alternative to OAC in such patients [17].  
           
Patients with prior GI bleeding 
Clearly,GI bleeding may be a serious medical condition, particularly in elderly AF patients with 
complex co-morbidities [155]. The estimated annual risk of GI bleeding in these patients ranges 
between 0.3% and 0.5% even without antithrombotic therapy [156]. Warfarin is associated with 
a 3-fold greater risk of major GI bleeding compared to placebo, whilst the combination of 
warfarin and aspirin doubles the risk of GI bleeding compared to warfarin monotherapy [156]. 
Antiplatelet drugs (such as aspirin or thienopyridines) cause bleeding by creating erosions and/or 
ulcers within the GI tract, and anticoagulant drugs (e.g., VKAs, heparins) may facilitate bleeding 
from pre-existing GI lesions [157, 158].    
A meta-analysis of 43 randomized controlled trials that compared NOACs to standard care 
(depending on the indication for OAC) in a total of 151,578 patients reported an increased 
overall risk of GI bleeding in patients taking NOACs (OR of 1.45; 95%CI, 1.07-1.97), but 
substantial heterogeneity was observed among the trials [159]. Of note, GI bleeding risk was the 
highest in patients treated for arterial thrombosis (i.e., acute coronary syndrome), in whom 
NOACs were co-administered with other antithrombotic drugs (OR 5.21; 95%CI, 2.58-10.53), 
intermediate in patients with venous thrombosis (OR 1.59; 95%CI, 1.03-2.44) or AF (OR 1.21; 
95%CI, 0.91-1.61) and the lowest in patients receiving NOACs for thromboprophylaxis after 
orthopaedic surgery (OR 0.78; 95%CI, 0.31-1.96). Compared to standard care, the drug-specific 
risk of GI bleeding tended to be lower with edoxaban (OR 0.31; 95%CI, 0.01-7.69), was similar 
to standard care with apixaban (OR 1.23; 95%CI, 0.56-2.73) and increased with dabigatran (OR 
1.58; 95%CI, 1.29-1.93) or rivaroxaban (OR 1.48; 95%CI, 1.21-1.82) [159].  
A pooled individual patient data meta-analysis of the trials comparing NOACs vs. warfarin in 
AF patients showed the increased risk of GI bleeding with NOACs as a whole compared to 
warfarin (RR 1.25; 95%CI, 1.01-1.55, p=0.043) [52]. The drug-specific GI bleeding rates in the 
trials of NOACs for stroke prevention in non-valvular AF are shown in Table 3. 
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In the main RE-LY trial report, dabigatran 110mg twice daily was associated with similar GI 
bleeding rates as warfarin, whilst the rates were significantly higher with dabigatran 150mg 
twice daily compared to warfarin (Table 3) [7]. The use of dabigatran 150mg twice daily during 
1 year would have resulted in 5 additional GI bleedings per thousand of patients [160]. GI 
bleeding rates were higher with concomitant use of antiplatelet drugs (i.e., aspirin and/or 
clopidogrel) or with decreasing creatinine clearance [44]. There was a significant interaction 
between age and GI bleeding risk with dabigatran 110mg twice daily in the RE-LY trial: whilst 
the risk of GI bleeding was similar with dabigatran 110mg or warfarin in patients younger than 
75 years (RR 0.82; 95%CI, 0.58-1.15), dabigatran 110mg was associated with significantly 
greater risk of GI bleeding in patients ≥75 years old (RR 1.39; 95%CI, 1.03-1.98), p for 
interaction 0.02 [44]. Overall, dabigatran was associated with a higher percentage of lower GI 
bleedings than warfarin (53% vs. 25%, respectively) [44]. Of note, a recent nationwide analysis 
of AF patients taking dabigatran reported no increase in GI bleeding rates compared to warfarin 
(indeed, the rates of GI bleeding were lower with dabigatran 110mg and similar with dabigatran 
150mg compared to warfarin) [161].   
The ROCKET-AF trial included older AF patients with more comorbidities (and a higher 
bleeding risk) compared with other NOAC trials in AF [8]. Rivaroxaban was associated with 
higher rates of GI bleeding events than warfarin [8, 162], resulting in 8 additional GI bleeds 
annually, per 1000 patients [160]. The anatomic sites of GI bleeding were not specified in the 
ROCKET-AF trial, and increased risk of GI bleeding was associated with age, concomitant 
antiplatelet drug therapy, lower creatinine clearance, anaemia, smoking, chronic obstructive 
pulmonary disease, male gender, diastolic blood pressure and prior GI bleeding [45]. Indeed, 
there was a significant interaction between the effects of rivaroxaban and history of prior GI 
bleeding (interaction p=0.002) – patients taking rivaroxaban were at increased risk of GI 
bleeding compared to those on warfarin if they had a history of prior GI bleed (HR 2.33; 95%CI, 
1.39-3.88), whilst the risk was comparable in patients with no history of prior GI in both 
treatment groups (HR 1.00; 95%CI, 0.86-1.16) [45].    
The rates of GI bleeding were similar in the apixaban and warfarin arms of the ARISTOTLE trial 
[9], as well as in the apixaban and aspirin arms of the AVERROES (Table 3) [51]. Two-thirds of 
all GI bleeding events in the ARISTOTLE trial were located in the upper GI tract, with no 
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significant difference between apixaban and warfarin (Table 3) [46]. Factors associated with an 
increased risk of major haemorrhage were older age, prior haemorrhage, prior stroke or TIA, 
diabetes, lower creatinine clearance, decreased hematocrit level and the use of aspirin or non-
steroidal anti-inflammatory drugs [46]. 
High-dose edoxaban was associated with significantly higher GI bleeding rates than warfarin, 
whilst the GI bleeding rates were lower with low-dose edoxaban compared to the warfarin 
treatment group (Table 3) [10]. In contrast to dabigatran, and similar to apixaban, about two 
thirds of GI bleeding events associated with edoxaban were located in the upper GI tract [10, 44, 
46]. 
Restarting OAC after a major GI bleeding.  
Prior GI bleeding is a risk factor for future bleeding events in patients taking OAC [20]. 
However, given a positive net clinical benefit of OAC in most AF patients [11-14], the history of 
GI bleeding itself should not be considered as an absolute contraindication for OAC. Indeed, it 
has been reported that cessation of warfarin therapy was associated with increased risk of 
thrombosis and death in patients who had experienced a GI bleeding [163]. Importantly, the 
timing of OAC resumption following a major GI haemorrhage should be guided by the cause and 
severity of GI bleeding and the individual patient stroke risk [160]. After resection of solid GI 
tumors, for example, the risk of bleeding returns to baseline as soon as haemostasis has been 
achieved, whilst the risk of recurrent GI bleeding events remains increased in patients with 
multiple GI angiectasias [16, 164]. In general, following a major GI haemorrhage OAC should 
be restarted after haemostasis has been secured and some GI lesion(s) healing has occurred 
[160], and gastric protection with proton pump inhibitors or H2 receptor blockers should be 
considered [100].    
 
Patients with hepatic insufficiency 
Impairment of liver function in patients taking OAC may increase the risk of bleeding by 
diminished synthesis of coagulation factors (both pro- and anticoagulant ones) and by altered 
anticoagulant drug metabolism and elimination. The liver has a high compensatory capacity 
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(hence, the degenerative decrease in liver function that occurs with increasing age usually does 
not become clinically relevant), but chronic liver diseases (such as hepatitis B or C, excessive 
alcohol ingestion, etc.) ultimately may result in sufficient destruction of liver parenchyma (i.e., 
liver cirrhosis) to cause clinically relevant hepatic insufficiency[165].  
Although reduction in pro- and anticoagulant factors and qualitative and quantitative platelet 
defects in hepatic failure correlate with severity of liver insufficiency, the prolongation of 
coagulation times (especially the prothrombin time and activated partial thromboplastin time as 
excellent markers of liver dysfunction) might not reliably reflect the extent of reduced 
coagulation, due to concomitant deficiency in the anticoagulant liver-dependent proteins which 
re-balances haemostasis and may protect from spontaneous bleeding. Thrombin is the final 
enzyme in the coagulation cascade and therefore global coagulation assays (e.g., thrombin 
generation) may better indicate the coagulation capacity in patients with hepatic insufficiency 
[166].  
Worsening liver function has been associated with subsequent bleeding in patients taking 
warfarin [167]. A recent retrospective study reported a 2-fold greater risk of bleeding and a lower 
mean time in therapeutic range in patients with chronic liver disease compared to those without 
(53.5% vs. 61.7%, p<0.001), and serum albumin or creatinine were the strongest predictors of 
both outcomes [168]. Since all NOACs undergo some hepatobiliary metabolism (dabigatran 
~20%, rivaroxaban ~34%, apixaban 75%, and edoxaban ~65%) hepatic impairment can affect 
the NOACs’ disposition and, hence, the intensity of their anticoagulation effect [169].  However, 
only a few patients with significant chronic liver disease were included in the landmark trials of 
NOACs in AF [7-10, 51], and data are lacking for the safety of NOACs in patients with liver 
dysfunction.   
The Child-Pugh scale is the most commonly used to describe the extent of chronic hepatic 
impairment by combining two symptoms (ascites and encephalopathy) with three laboratory 
parameters (serum albumin, serum bilirubin and prothrombin time), thus categorizing chronic 
liver disease into mild, moderate or severe hepatic dysfunction (i.e., grades A, B and C, 
respectively). Available data suggest that dabigatran [170], rivaroxaban [171], apixaban [172] 
and edoxaban [169] can be used in patients with mild hepatic impairment (Child-Pugh A), 
dabigatran and apixaban can be given with caution in moderate hepatic dysfunction (Child-Pugh 
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B) and normal levels of the liver enzymes, but all three drugs should be avoided in patients with 
severe liver impairment (Child-Pugh C) [169].  
A recent meta-analysis of 29 phase III randomised controlled trials evaluating a total of 152,116 
patients taking dabigatran, rivaroxaban, apixaban, edoxaban or darexaban versus control 
treatment (i.e., vitamin K antagonists, low molecular weight heparin or placebo) reported similar 
risk of drug-induced liver injury with NOACs as a whole compared to control therapy (RR 0.90; 
95%CI, 0.72-1.13) [173]. Similar results were obtained on individual NOAC analyses compared 
to VKAs or other control therapies (drug-induced liver injury was defined as transaminase and 
total bilirubin elevations of >3-fold and >2-fold the upper limit of normal, respectively, and all 
included trials were rated as having low risk of bias).   
Until more data are available, OAC should be used with a caution in patients with mild to 
moderate liver function impairment. Regular clinical follow-up on every few months and careful 
laboratory monitoring of liver function seem prudent in this population of AF patients.   
 
Patients with malignancy 
Patients with malignancies have an increased baseline risk of bleeding, dependent on the cancer 
type and stage, renal and liver function and the presence or absence of thrombocytopenia. In 
addition, bleeding risk could also be aggravated by chemotherapy. The risk of clinically relevant 
bleeding without anticoagulation in patients with advanced cancer is estimated to be around 
10%, although data are lacking [174]. 
Available data on OAC in patients with a malignancy mostly come from clinical randomized 
trials on deep venous thromboembolism. These data suggest there is a comparable risk of major 
bleeding with VKAs and low molecular weight heparins (around 6% during the 3-6-month 
treatment period), and a pooled analysis of NOACs vs. warfarin revealed no significant 
difference in major bleeding (HR 1.03; 95%CI, 0.44-2.39) or clinically relevant bleeding (HR 
0.95; 95%CI, 0.71-1.29) between the treatment groups [174]. However, data on the use of OAC 
in AF patients with cancer are sparse, and individual risk assessment is necessary. Of note, it has 
been shown that cancer patients with recent bleeding (within the last 30 days) or CrCl of less 
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than 30mL/min, those with immobility of ≥4 days and patients with metastatic disease have 
significantly greater risk of OAC-associated bleeding compared to other patients with a 
malignancy [175].  
     
Selection of optimal thromboprophylaxis in AF in clinical practice 
An overview of antithrombotic drugs is presented in Table 4. Overall, many issues in the field of 
thromboprophylaxis in AF patients are still to be solved. Until more information on optimal 
thromboprophylaxis in various AF populations is acquired, a proposal for clinical decision-
making is shown in Figures 1 and 2. In general, when choosing between NOACs and VKAs, the 
decision could be aided by reliable prediction of the quality of anticoagulation with VKAs in 
terms of individual TTR. Recently, a relatively simple clinical risk score with an acronym 
SAMe-TT2R2 (Figure 3) has been formulated and several observational studies showed that the 
score had a good ability to identify patients who will have good TTR, whilst a SAMe-TT2R2 
value of >2 was predictive of poor TTR, all-cause mortality and composite endpoint of 
thromboembolic events, major bleeding and mortality [176-180]. It has been postulated that 
OAC-naive AF patients with a SAMe-TT2R2 score of 0 to 2 could be assigned to a VKA, whilst 
patients with a SAMe-TT2R2 score of >2 should start a NOAC straightforward (Figure 3).  
 
Conclusions   
Most AF patients are indicated for oral anticoagulant therapy to prevent stroke or systemic 
embolism, and increased risk of bleeding complications should not preclude consideration of 
adequate thromboprophylaxis. Available evidence shows that any oral anticoagulant therapy is 
better than no therapy or aspirin in almost all AF patients, regardless of the bleeding risk level. 
NOACs offer a significant safety advantage over VKAs, particularly in patients at increased risk 
of bleeding events such as the elderly and patients with impaired renal function or prior stroke or 
TIA, whilst more information is needed to inform better use of oral anticoagulant drugs in 
patients with prior ICH, end-stage renal disease, severe hepatic insufficiency or active malignant 
disease. Patients at increased risk of both stroke and bleeding events should be prescribed oral 
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anticoagulant therapy whenever possible, and regular clinical follow-up of these patients is 
mandatory.      
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Table 1. Stages of chronic kidney disease [181] and eGFR stratified risk of stroke [60, 181].  
 
CKD  
Stage I 
Normal or 
increased GFR 
Stage II 
Mild 
Stage IIIa/IIIb 
Moderate 
Stage IV  
Severe 
CKD Stage V 
End-stage 
 
eGFR 
ml/min/1.73m
2
 
≥90 60-89 45-59 / 30-44 15-29 <15  
eGFR stratified 
stroke risk 
HR (95%CI) 
eGFR>60 
1.07 (0.98-1.56) 
eGFR 40-60 
1.28 (1.04-1.56) 
eGFR <40 
1.77 (1.32-2.38) 
 
 
CKD: chronic kidney disease; GFR: glomerular filtration rate; HR: Hazard Ratio; CI: 
Confidence Interval. 
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Table 2. Intracranial bleeding event rates in randomized phase III trials of NOACs vs. 
Warfarin (or aspirin) for stroke prevention in patients with non-valvular AF. 
Trial Annualized ICH rates with a NOAC vs. Warfarin (or Aspirin) 
RE-LY [117]  Warfarin 
Dabigatran 
150mg bid 
RR (95%CI) 
Dabigatran 
150mg bid vs. 
Warfarin 
P 
Dabigatran 
110mg bid 
RR (95%CI) 
Dabigatran 
110mg bid vs. 
Warfarin 
P 
All ICHs 
(n=154) 
90 (0.76) 37 (0.31) 0.40 (0.27-0.59) <0.001 27 (0.23) 0.30 (0.19-0.45) <0.001 
ROCKET-AF 
[50] 
Warfarin Rivaroxaban HR (95%CI) P    
All ICHs 
(n=172) 
84 (0.7) 55 (0.5) 0.67 (0.47-0.93) 0.02    
ARISTOTLE 
[9] 
Warfarin Apixaban HR (95%CI) P    
All ICHs 
(n=174) 
122 
(0.80) 
52 (0.33) 0.42 (0.30-0.58) <0.001    
ENGAGE-AF 
[10] 
Warfarin 
Edoxaban  
60mg OD 
HR (95%CI) P 
Edoxaban  
30mg OD 
HR (95%CI) P 
All ICHs 
(n=234) 
132 
(0.85) 
61 (0.39) 0.47 (0.34-0.63) <0.001 41 (0.26) 0.30 (0.21-0.43) <0.001 
AVERROES 
[51] 
Aspirin Apixaban HR (95%CI) P    
All ICHs 
(n=24) 
13 (0.41) 11 (0.35) 0.85 (0.38-1.90) 0.69    
NOAC: Non-vitamin K oral anticoagulant; AF: Atrial fibrillation; ICH: Intracranial haemorrhage; RR: Relative Risk; HR: 
Hazard Ratio; CI: Confidence Interval.  
RE-LY - Randomized Evaluation of Long-term Anticoagulant Therapy; ROCKET AF - Rivaroxaban Once Daily Oral Direct 
Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation; 
ARISTOTLE - Apixaban for Reduction In Stroke and Other Thromboembolic Events in Atrial Fibrillation; ENGAGE AF-TIMI 
48 - Effective Anticoagulation with factor Xa next Generation in Atrial Fibrillation; AVERROES - Apixaban Versus 
Acetylsalicylic Acid [ASA] to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K 
Antagonist Treatment.  
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Table 3. Major gastrointestinal bleeding event rates in randomized phase III trials of 
NOACs vs. Warfarin (or aspirin) for stroke prevention in patients with non-valvular AF. 
Trial Annualized GI bleeding rates with a NOAC vs. Warfarin (or Aspirin) 
RE-LY Warfarin 
Dabigatran 
150mg bid 
RR (95%CI) 
Dabigatran 
150mg bid vs. 
Warfarin 
P 
Dabigatran 
110mg bid 
RR (95%CI) 
Dabigatran 
110mg vs. 
Warfarin 
P 
Main trial 
report [7] 
1.02 1.51 1.50 (1.19-1.89) <0.001 1.12 1.10 (0.86-
1.41) 
0.43 
Subanalysis 
[44] 
1.25 1.85 1.49 (1.21-1.84) 0.002 1.36 1.09 (0.87-
1.36) 
0.44 
        
ROCKET-AF Warfarin Rivaroxaban HR (95%CI) 
Rivaroxaban vs. 
Warfarin 
P    
Main trial 
report [8] 
2.2 3.2  <0.001    
Subanalysis 
[162] 
1.24 2.00 1.61 (1.30-1.99) <0.001    
        
ARISTOTLE Warfarin Apixaban HR (95%CI) 
Apixaban vs. 
Warfarin 
P    
Main trial 
report [9] 
0.86 0.76 0.89 (0.70-1.15) 0.37    
Subanalysis: 
[46] 
0.88 0.78 0.89 (0.70-1.14) 0.35    
Upper GI 
bleeding 
0.56 0.43 0.76 (0.55-1.05) 0.09    
Lower GI 
bleeding 
0.24 0.25 1.06 (0.67-1.67) 0.80    
        
ENGAGE-AF Warfarin 
Edoxaban 
60mg OD 
HR (97%CI) 
Edoxaban 60mg 
OD vs. 
Warfarin 
P 
Edoxaban 
30mg OD 
HR (97%CI) 
Edoxaban 
30mg OD vs. 
Warfarin 
P 
Main trial 
report[10] 
1.23 1.51 1.23 (1.02-1.50) 0.03 0.82 0.67 (0.53-
0.83) 
<0.001 
Upper GI 
bleeding 
0.71 0.91 1.27 (0.99-1.63) 0.06 0.56 0.78 (0.59-
1.03) 
0.08 
Lower GI 
bleeding 
0.52 0.62 1.20 (0.89-1.61) 0.23 0.28 0.54 (0.37-
0.77) 
<0.001 
        
AVERROES Aspirin Apixaban HR (95%CI) 
Apixaban vs. 
Aspirin 
P    
Main trial 
report [51] 
0.4 0.4 0.85 (0.38-1.90) 0.69    
        
NOAC: non-vitamin K oral anticoagulant; AF: atrial fibrillation; GI: gastrointestinal; RR: Relative Risk; HR: Hazard Ratio; CI: 
Confidence Interval.  
RE-LY - Randomized Evaluation of Long-term Anticoagulant Therapy; ROCKET AF - Rivaroxaban Once Daily Oral Direct 
Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation; 
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ARISTOTLE - Apixaban for Reduction In Stroke and Other Thromboembolic Events in Atrial Fibrillation; ENGAGE AF-TIMI 
48 - Effective Anticoagulation with factor Xa next Generation in Atrial Fibrillation; AVERROES - Apixaban Versus 
Acetylsalicylic Acid [ASA] to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K 
Antagonist Treatment. 
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Table 4. Pharmacological thromboprophylaxis in atrial fibrillation – an overview. 
Drug Comparator Stroke reduction (95% CI) Comment 
Antiplatelet drugs    
Aspirin 
(meta-analysis) [6] 
Placebo  
All strokes: 19% (-1% to 35%)  
Ischemic strokes: 21% (-1% to 38%)  
 Aspirin slightly better than placebo (no statistical significance) 
 Only 325mg daily shown to be beneficial (lower doses were similar to placebo) 
 Aspirin was not effective in patients ≥75 years and in the prevention of severe 
strokes 
Aspirin + 
Clopidogrel 
(ACTIVE A) [182] 
Aspirin 28%;  RR 0.72 (0.62 to 0.84)  
 The combination of aspirin plus clopidogrel was associated with >50% higher risk 
of major bleeding compared with aspirin alone (RR 1.56; 95%CI, 1.28%-1.89%)  
 Major bleeding rates were comparable with the rates in some warfarin trials 
VKAs    
Warfarin 
(meta-analysis) [6] 
Placebo 
All strokes: 64% (49% to 74%)  
Ischemic strokes: 67% (54% to 77%)  
 A 26% (3%-43%) reduction in all-cause mortality with warfarin 
Warfarin 
(meta-analysis) [6]  
Aspirin 37% (23% to 48%)  
 The risk of ICH was doubled with warfarin, but the absolute risk increase was small 
(0.2% per year) 
Warfarin 
(ACTIVE W) [183]  
Aspirin +  
Clopidogrel 
40% (18% to 56%) 
 The trial was stopped early, because of clear evidence of oral VKA superiority over 
clopidogrel plus aspirin 
NOACs    
Apixaban 
(AVERROES) [51]  
Aspirin 
Stroke or SE: 55%;  
RR 0.45 (0.32 to 0.62)   
Ischemic stroke: 63%;  
RR 0.37 (0.25 to 0.55)  
 No significant difference in major bleeding with apixaban vs. aspirin (RR 1.13, 
0.74-1.75)  
 No significant difference in ICH (RR 0.85, 0.38-1.90) 
 Lower risk of permanent drug discontinuation with apixaban (RR 0.88, 0.78-0.99)  
NOACs 
(meta-analysis) [52] 
Warfarin 
Stroke or SE: 19%;  
RR 0.81 (0.73 to 0.91) 
Ischemic stroke 8%;  
RR 0.92 (0.83 to 1.02)  
 Significant reduction of haemorrhagic stroke (RR 0.49, 0.38-0.64) 
 Significant reduction of ICH (RR 0.48, 0.39-0.59) 
 Significant reduction of all-cause mortality (RR 0.90, 0.85-0.95) 
 Increased risk of GI bleeding (RR 1.25, 1.01-1.55) 
CI: Confidence Interval; ACTIVE A: Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events Aspirin; RR: Relative Risk; VKA: 
Vitamin K antagonist; ACTIVE W: Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events Warfarin; ICH: Intracranial 
haemorrhage; NOAC: Novel oral anticoagulants; AVERROES: Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients who have 
Failed or are Unsuitable for Vitamin K Antagonist Treatment; GI: Gastrointestinal. 
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Figure 1. Selection of optimal thromboprophylaxis in AF. 
Proceed to the choice of OAC 
(Figure 2)
Selection of optimal thromboprophylaxis in AF patients at risk of thromboembolism
Contraindications to OAC?
NO YES
LAA occlusion 
(includes the need for 
antiplatelet therapy)
Patient acceptance of OAC?
(adequate information provided)
NOYES
Bleeding risk 
assessment 
(HAS-BLED)
HAS-BLED ≤2 HAS-BLED ≥3
Proceed to the choice of OAC 
(Figure 3)
Address the modifiable 
bleeding risk factors 
(e.g., hypertension, concomitant 
drug or alcohol intake, labile INRs)
Non-modifiable bleeding risk 
factors - ‘special populations’ 
(e.g., elderly, chronic kidney disease, 
history of  prior bleeding)
 
OAC: oral anticoagulation; LAA: left atrial appendage.  
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Figure 2. Selection of OAC in ‘special’ AF populations. 
Selection of OAC in ‘special’ AF populations at risk of thromboembolism 
and increased risk of bleeding due to non-modifiable bleeding risk factors
Prior bleeding event?
NO
YES
ICH
GI
Age>75y?
NOYES
Apix
5mg* bid
Riva 
20mg od
Dabi
110mg bid
VKA
Edox
60mg od
Edox
30mg od
Relevant CKD?
NO
(CrCl≥50ml/min)
YES
CrCl
30-49ml/min
CrCl 1
5-29ml/min
Apix
5mg* bid
Localization? 
(consult a neurologist)
Apix
5mg* bid
Riva 
15mg od
Dabi
110mg bid
Riva 
15mg od
Apix
2.5mg bid
VKA
SUBDURAL
DEEP 
INTRACEREBRAL
LOBAR 
(SUB)CORTICAL
Resume a 
NOAC after 
‘acute’ phase
Consider 
resuming 
a NOAC
Individual 
patient  risk 
assessment
The highest risk 
of recurrent 
ICH, consider 
LAA occlusion
Edox
30mg od
Edox
30mg od
Secure haemostasis and 
verify the lesion healing
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*Apixaban dose should be halved to 2.5mg bid in the presence of 2 of the following criteria: increased serum creatinine of 
≥133μmol/l, age ≥80 years and/or body weight ≤60kg; §Edoxaban dose should be halved in the presence of any of the following: body 
weight <60kg, creatinine clearance <50ml/min or verapamil or quinidine use.  
CKD: chronic kidney disease; GI: gastrointestinal; ICH: intracranial haemorrhage, NOAC: non-vitamin K antagonist oral 
anticoagulant; VKA: vitamin-K antagonist; LAA: left atrial appendage; bid: twice daily; od: once daily.  
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Figure 3. The choice of OAC for thromboprophylaxis in AF. 
Component Points
S Sex (female) 1
A Age (<60 years) 1
Me Medical history* 1
T Treatment (interacting drugs, e.g., 
amiodarone)
1
T Tobacco use (within 2 years) 2
R Race (non-Caucasian) 2
*More than two of the following: hypertension, diabetes mellitus, coronary artery disease/myocardial infarction, 
peripheral arterial disease, congestive heart failure, previous stroke, pulmonary disease, and hepatic or renal disease.  
Patient already taking a VKA?
NO
YES
SAMe-TT2R2 ≤2   SAMe-TT2R2 >2   
VKAs 
(or NOACs)   
NOACs   
Labile INR
(TTR<70%)
TTR≥70%, 
patient 
satisfied 
with VKA 
VKAs   
 
VKA: vitamin K antagonist; NOAC: non-vitamin K antagonist; INR: international normalized ratio; TTR: time in therapeutic range. 
